BTS
EPZM

BB&T Securities’s Epizyme, Inc EPZM Stock Holding History

BB&T Securities’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,000
Closed -$169K – 1640
2018
Q3 		$169K Hold
16,000
– – ﹤0.01% 1505
2018
Q2 		$216K Buy
16,000
+5,000
+45% +$77.8K ﹤0.01% 1425
2018
Q1 		$195K Hold
11,000
– – ﹤0.01% 1410
2017
Q4 		$138K Hold
11,000
– – ﹤0.01% 1393
2017
Q3 		$209K Sell
11,000
-1,000
-8% -$15.3K ﹤0.01% 1284
2017
Q2 		$181K Buy
+12,000
New +$181K ﹤0.01% 1305

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BB&T Securities's EPZM Position: Q4 2018 in Review

BB&T Securities sold out of Epizyme, Inc (EPZM) in Q4 2018, closing a stake of 16,000 shares — an estimated $169K sold.

BB&T Securities first reported a position in EPZM in Q2 2017 and held it in 6 quarters. The position peaked at $216K in Q2 2018. 105 funds tracked by Wall St. Rank hold EPZM as of Q4 2018.

  • BB&T Securities reported no remaining Epizyme, Inc position as of Q4 2018 after selling out during the quarter.
  • BB&T Securities sold 16,000 Epizyme, Inc shares in Q4 2018, an estimated $169K.
  • BB&T Securities first reported a position in Epizyme, Inc in Q2 2017 and held it in 6 quarters.
  • BB&T Securities's Epizyme, Inc position peaked at $216K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.